title: Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.
abstract: To explore an approach for death receptor targeting in cancer, we developed murine mAbs to human death receptor 4 (DR4). The mAb 4H6 (IgG1) competed with Apo2L/TNF-related apoptosis-inducing ligand (DR4's ligand) for binding to DR4, whereas mAb 4G7 (IgG2a) did not. In vitro, both mAbs showed minimal intrinsic apoptosis-inducing activity, but each triggered potent apoptosis upon cross-linking. In a colon tumor nude mouse model in vivo, mAb 4H6 treatment without addition of exogenous linkers induced apoptosis in tumor cells and caused complete tumor regression, whereas mAb 4G7 partially inhibited tumor growth. An IgG2a isotype switch variant of mAb 4H6 was much less effective in vivo than the parent IgG1-4H6, despite similar binding affinities to DR4. The same conclusion was obtained by comparing other IgG1 and IgG2 mAbs to DR4 for their anti-tumor activities in vivo. Thus, the isotype of anti-DR4 mAb may be more important than DR4 binding affinity for tumor elimination in vivo. Anti-DR4 mAbs of the IgG1 isotype may provide a useful tool for investigating the therapeutic potential of death receptor targeting in cancer.
authors: Department of Antibody Technology, Genentech, South San Francisco, CA 94080, USA.
authors: A
authors: A
authors: Chuntharapai
authors: K
authors: K
authors: Dodge
authors: K
authors: K
authors: Grimmer
authors: K
authors: K
authors: Schroeder
authors: S A
authors: SA
authors: Marsters
authors: H
authors: H
authors: Koeppen
authors: A
authors: A
authors: Ashkenazi
authors: K J
authors: KJ
authors: Kim
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000502:physiology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis / Q000276:immunology; D001666:Binding Sites, Antibody; D004195:Disease Models, Animal; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000502:physiology*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000502:physiology*; D007132:Immunoglobulin Isotypes / Q000008:administration & dosage / Q000502:physiology*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology* / Q000517:prevention & control*; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured / Q000637:transplantation
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D007074:Immunoglobulin G; D007132:Immunoglobulin Isotypes; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor; C105190:TNFRSF10A protein, human